However, in 1976, just as multi-disciplined marijuana research should have been going into its second, third, and fourth generation studies (see Therapeutic Potential of Marijuana and NORML federal files), a “surprise” United States government policy again forbade all promising federal research into marijuana’s therapeutic effects.

    This time, the research ban was accomplished when American pharmaceutical companies successfully petitioned the federal government to be allowed to finance and judge 100% of the research.

    The previous 10 years of research had indicated a tremendous promise for the therapeutic uses of natural cannabis, and this potential was quietly turned over to corporate hands—not for the benefit of the public, but to suppress the information.

    This plan, the drug manufacturers petitioned, would allow our private drug companies time to come up with patentable synthetics of the cannabis molecules at no cost to the federal government, and a promise of “no highs.”

    In 1976, the Ford Administration, NIDA, and the DEA said, in effect, no American independent (read: university) research or federal health program would be allowed to again investigate natural cannabis derivatives for medicine. This agreement was made without any safeguards guaranteeing integrity on the part of the pharmaceutical companies; they were allowed to regulate themselves.

    Private pharmaceutical corporations were allowed to do some “no high” research, but it would be only Delta-9 THC research, not any of the 400 other potentially therapeutic isomers in cannabis.

    Why did the drug companies conspire to take over marijuana research? Because recent U.S. government research (1966-1976) had indicated or confirmed through hundreds of studies that even “natural” crude cannabis was the “best and safest medicine of choice” for many serious health problems.

the authorized on-line version of Jack Herer’s “The Emperor Wears No Clothes”

previous page	Chapter 6	next page